Drugs / LHA510
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02076919 | Feb → Jun 2014 | age-related macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02355028 | Mar 2015 → Sep 2016 | wet macular degeneration | Alcon, a Novartis Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LHA510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02076919 ↗ |
| Route | Topical | “topically administered in Part 1 and Part 2” NCT02076919 ↗ |